The Recommendations the UN High-Level Access to Medicines Panel Should Be Making

Stephen Ezell July 14, 2016
July 14, 2016

A UN high-level panel on access to medicines gives the game away from the start by taking a skeptical attitude toward intellectual property (IP), erroneously postulating a "policy incoherence" between IP and access to medicines, writes Stephen Ezell in Innovation Files. Moreover, the panel’s exclusive focus on IP belies the notion that its work is genuinely concerned with tackling the broad range of difficult challenges impacting global medicine access. A meaningful final report should recognize the fundamental role IP plays in medical discovery, the damage that price controls cause, and the need to invest more in public health systems while reducing tariffs and taxes on biopharmaceutical products.